Gudrun Hörnquist
Directeur/Membre du Conseil chez Rare Thyroid Therapeutics International AB
Profil
Gudrun Hörnquist is currently a Director at Rare Thyroid Therapeutics International AB.
Previously, he worked as a Director-Regulatory Business Services at Swedish Orphan International Holding AB from 1995 to 2010.
Postes actifs de Gudrun Hörnquist
| Sociétés | Poste | Début |
|---|---|---|
Rare Thyroid Therapeutics International AB
 Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Rare Thyroid Therapeutics International AB provides thyroid therapeutics research services. The company is headquartered in Stockholm, Sweden. | Directeur/Membre du Conseil | - |
Anciens postes connus de Gudrun Hörnquist
| Sociétés | Poste | Fin |
|---|---|---|
Swedish Orphan International Holding AB
 Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | Conseiller Juridique Général | 03/06/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | Health Technology |
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics International AB BiotechnologyHealth Technology Rare Thyroid Therapeutics International AB provides thyroid therapeutics research services. The company is headquartered in Stockholm, Sweden. | Health Technology |